老年心衰患者PCI中经皮心室辅助装置与主动脉内球囊反搏的目标试验模拟比较
本研究基于美国Medicare数据库,纳入2017至2020年65-99岁接受PCI的收缩性心衰患者,采用目标试验模拟框架比较PCI联合pVAD与联合IABP的临床结局。经倾向评分匹配后,1年MACE风险在pVAD组为55.4%,IABP组为54.7%(aHR 0.95,95%CI 0.83-1.10),未发现两组在死亡率或输血等结局上存在差异。
要点
- 老年收缩性心衰患者PCI时使用pVAD与IABP的1年MACE风险无显著差异。
- 1年死亡率(aHR 0.94,95%CI 0.79-1.12)及术后输血风险亦无差异。
- 敏感性分析结果一致,不支持pVAD优于IABP的结论。
核心结论
- 在老年收缩性心衰接受PCI的患者中,pVAD与IABP相比未显示临床结局差异。
研究设计与样本
- 基于美国Medicare按服务收费数据库的目标试验模拟研究,纳入2017-2020年65-99岁接受PCI的收缩性心衰患者。
- 共纳入5823例患者,经倾向评分匹配控制58个基线协变量后匹配2096例。
- 随访从索引PCI日期至最长1年,比较pVAD vs IABP的MACE及院内结局。
主要发现
- 1年MACE风险:pVAD组55.4%(95%CI 52.2-58.5),IABP组54.7%(95%CI 51.4-57.8),aHR 0.95(95%CI 0.83-1.10)。
- 1年死亡率:aHR 0.94(95%CI 0.79-1.12)。
- 术后输血:调整风险比1.07(95%CI 0.75-1.52)。
- 其他结局在两组间未见差异,敏感性分析结果一致。
临床怎么用
- 对于老年收缩性心衰患者PCI,pVAD与IABP的临床结局相似,选择时需综合评估。
局限性
- 观察性设计可能受残余混杂影响。
- 仅纳入Medicare按服务收费受益人,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Percutaneous ventricular assist devices (pVAD) have been increasingly used to support haemodynamics during percutaneous coronary interventions (PCI). Since older patients with coronary artery disease and heart failure (HF) are less likely to undergo open heart surgery, given the higher risk of perioperative complications, the analyses on the benefits of pVAD for older patients with HF receiving PCI will be informative. METHODS: We included Medicare fee-for-service beneficiaries aged 65-99 years with systolic HF receiving PCI from 2017 to 2020. Using a target trial emulation framework, we followed the patients from the date of the index PCI to the maximum of 1 year and examined the incidence of major adverse cardiovascular events (MACE: composite of all-cause mortality, HF readmission, acute myocardial infarction, and stroke), as well as in-hospital outcomes, including postprocedural transfusions, of patients treated with PCI plus pVAD versus PCI plus intra-aortic balloon pump (IABP). We used the propensity score matching approach to control for 58 baseline covariates and applied a Cox regression model to estimate adjusted hazard ratio (aHR). RESULTS: We included 5823 patients, from whom 2096 patients were matched. The risk of 1-year MACE was 55.4% (95% CI 52.2-58.5) in the pVAD group versus 54.7% (95% CI 51.4 to 57.8) in the IABP group, with aHR of 0.95 (95% CI 0.83 to 1.10). We did not find evidence that other outcomes differed between patients treated with PCI plus pVAD versus PCI plus IABP, including 1-year mortality (aHR, 0.94; 95% CI,0.79 to 1.12) and postprocedural transfusions (adjusted risk ratio, 1.07; 95% CI 0.75 to 1.52). Our findings were consistent across several sensitivity analyses. CONCLUSIONS: This observational study using the Medicare databases in the USA did not find evidence that clinical outcomes differed between older patients with systolic HF receiving PCI with pVAD vs PCI plus IABP.
引用
- Watanabe, Miyamoto, Ueyama, et al. Percutaneous ventricular assist devices for percutaneous coronary interventions in older patients with heart failure: a target trial emulation. Heart. 2026. PMID: 41218925. doi:10.1136/heartjnl-2025-326949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。